Our initial focus is on developing novel immuno-oncology (IO) therapeutics targeting butyrophilins/butyrophilin-like proteins [BTN(L)s] to treat a range of solid tumors and hematologic cancers. Initially, our programs were centered around the powerful mechanism of action of γ9δ2 T cells, however, as our understanding of the BTN(L) biology has evolved we have utilized this knowledge to generate intellectual property around targeting other immune cell populations to create a diversified and deep pipeline.
Differentiated and Diversified Pipeline with First-in-class Potential
Abbreviations: 1L/2L, first-second-line treatment; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; AV, azacitidine-venetoclax; BTN3A, butyrophilin 3A receptor; DLBCL, diffuse large B cell lymphoma; EV, enfortumab vedotin; FPI, first patient-in; HSCT, hematopoetic stem cell transplantation; IL2 ,interleukin-2; IO, immuno-oncology therapies; MEL, melanoma; SoC, standard of care; UCC, urothelial cell carcinoma.